Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Viral clearance 59% Improvement Relative Risk Time to viral- 52% Zhao et al. Favipiravir for COVID-19 RCT LATE TREATMENT Is late treatment with favipiravir beneficial for COVID-19? RCT 55 patients in China Improved viral clearance with favipiravir (not stat. sig., p=0.059) Zhao et al., Int. Immunopharmacology, doi:10.1016/j.intimp.2021.107702 Favors favipiravir Favors control

Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: a multicenter, open-label, randomized trial

Zhao et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107702
Zhao et al., Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: a.., International Immunopharmacology, doi:10.1016/j.intimp.2021.107702
Apr 2021   Source   PDF  
  All Studies   Meta
RCT with 55 patients (36 favipiravir, 19 control) who were PCR+ after recovery, showing improved viral clearance with treatment.
risk of no viral clearance, 59.0% lower, RR 0.41, p = 0.06, treatment 7 of 36 (19.4%), control 9 of 19 (47.4%), NNT 3.6.
time to viral-, 52.4% lower, relative time 0.48, p = 0.04, treatment 36, control 19, inverted to make RR<1 favor treatment.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zhao et al., 21 Apr 2021, Randomized Controlled Trial, China, peer-reviewed, 25 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial
Hong Zhao, Chi Zhang, Qi Zhu, Xianxiang Chen, Guilin Chen, Wenjin Sun, Zuohan Xiao, Weijun Du, Jing Yao, Guojun Li, Yanhua Ji, Niuniu Li, Yujin Jiang, Ying Wang, Qingjin Zeng, Wei Li, Beilei Gong, Xianyou Chang, Feng Zhu, Xiufeng Jiang, Jiawen Li, Zhao Wu, Yingxia Liu, Peng Peng, Guiqiang Wang
International Immunopharmacology, doi:10.1016/j.intimp.2021.107702
Background: The clinical characteristics and treatment of patients who tested positive for COVID-19 after recovery remained elusive. Effective antiviral therapy is important for tackling these patients. We assessed the efficacy and safety of favipiravir for treating these patients. Methods: This is a multicenter, open-label, randomized controlled trial in SARS-CoV-2 RNA re-positive patients. Patients were randomly assigned in a 2:1 ratio to receive either favipiravir, in addition to standard care, or standard care alone. The primary outcome was time to achieve a consecutive twice (at intervals of more than 24 h) negative RT-PCR result for SARS-CoV-2 RNA in nasopharyngeal swab and sputum sample. Results: Between March 27 and May 9, 2020, 55 patients underwent randomization; 36 were assigned to the favipiravir group and 19 were assigned to the control group. Favipiravir group had a significantly shorter time from start of study treatment to negative nasopharyngeal swab and sputum than control group (median 17 vs. 26 days); hazard ratio 2.1 (95% CI [1.1-4.0], p = 0.038). The proportion of virus shedding in favipiravir group was higher than control group (80.6% [29/36] vs. 52.6% [10/19], p = 0.030, respectively). C-reactive protein decreased significantly after treatment in the favipiravir group (p = 0.016). The adverse events were generally mild and self-limiting. Conclusion: Favipiravir was safe and superior to control in shortening the duration of viral shedding in SARS-CoV-2 RNA recurrent positive after discharge. However, a larger scale and randomized, double-blind, placebocontrolled trial is required to confirm our conclusion.
consent form. Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Appendix A. Supplementary material Supplementary data to this article can be found online at https://doi. org/10.1016/j.intimp.2021.107702.
An, Liao, Xiao, Qian, Yuan et al., Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test, medRxiv
Bai, Mu, Kargbo, Song, Niu et al., Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, Clin. Infect. Dis
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the Treatment of Covid-19 -Preliminary Report, New Engl. J. Med
Cai, Yang, Liu, Chen, Shu et al., Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Cao, Wang, Wen, Liu, Wang et al., A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N. Engl. J. Med
Chen, Zhang, Yang, Wang, Zhai et al., Fangcang shelter hospitals: a novel concept for responding to public health emergencies, Lancet
Coomes, HaghbayanFavipiravir, an antiviral for COVID-19?, J. Antimicrobial Chemotherapy
Diao, Wang, Tan, Chen, Liu et al., Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19), Front. Immunol
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, New Engl. J. Med
Grubaugh, Hanage, Rasmussen, Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear, Cell
Hong, Cao, Liu, Lin, Zhou et al., Prolonged presence of viral nucleic acid in clinically recovered COVID-19 patients was not associated with effective infectiousness, Emerg. Microbes. Infect
Hung, Lung, Tso, Liu, Chung et al., Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial, Lancet
Korber, Fischer, Gnanakaran, Yoon, Theiler et al., Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus, Cell
Lan, Xu, Ye, Xia, Wang et al., Positive RT-PCR Test Results in Patients Recovered From COVID-19, JAMA
Li, Guan, Wu, Wang, Zhou et al., Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia, New Engl. J. Med
Li, Zhang, Wu, Wang, Zhao, The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial, Trials
Ling, Xu, Lin, Tian, Zhu et al., Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients, Chin. Med. J
Mei, Li, Du, Yuan, Li et al., Assessment of patients who tested positive for COVID-19 after recovery, Lancet Infect. Dis
Pan, Kok, Eikelenboom, Horsfall, Jörg et al., The mental health impact of the COVID-19 pandemic on people with and without depressive, anxiety, or obsessive-compulsive disorders: a longitudinal study of three Dutch case-control cohorts, Lancet Psychiatry
Qu, Kang, Cong, Positive result of Sars-Cov-2 in sputum from a cured patient with COVID-19, Travel Med. Infect. Dis
Song, Fu, Liu, Luo, Wang et al., Mental health status of medical staff in emergency departments during the Coronavirus disease 2019 epidemic in China, Brain Behav. Immun
Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ (Clinical research ed
Tang, Wu, Li, Song, Yao et al., On the origin and continuing evolution of SARS-CoV-2, Natl. Sci. Rev
Vijayvargiya, Esquer Garrigos, Almeida, Gurram, Stevens et al., Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof), Mayo Clin. Proc
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet
Yang, Jiang, Wang, Tang, Fang et al., Viral RNA level, serum antibody responses, and transmission risk in recovered COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a population-based observational cohort study, Emerg. Microbes. Infect
Yao, He, Li, Zhang, Wang et al., Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient, Cell Res
Zhou, Liu, Liu, Cause analysis and treatment strategies of "recurrence" with novel coronavirus pneumonia (COVID-19) patients after discharge from hospital (in Chinese), Chin. J. Tuberculosis Respiratory Dis
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop